CHMP Positive Opinion Based on Phase 3 Trial Data for Progression-Free Survival After Induction Therapy
The European Medicines Agency’s CHMP has issued a positive opinion for the combination of Lurbinectedin and Atezolizumab to treat advanced compact cell lung cancer (SCLC). This regulatory milestone provides a ... Read More